Lunai Bioworks Inc. (LNAI) Form 10-Q — May 15, 2026
Lunai Bioworks reported a net loss of $1.55 million for the nine months ended March 31, 2026, with minimal revenue of $20,942 from a single research services contract. The company holds only $3.16 million in cash against a working capital deficit of $15.55 million and an accumulated deficit of $512 million, prompting explicit going-concern language in the financial statements. The filing discloses severe capital structure distress, including a 1-for-10 reverse stock split effective in September 2025 and a subsequent board approval for a further reverse split ranging from 1:3 to 1:30 to maintain Nasdaq listing compliance.
Key figures
- Revenue
- 20942
- Total Debt
- 19413968
- Cash Position
- 3155272
- Shares Outstanding
- 35772800
- Atm Proceeds
- 4499551
- Gain On Bankruptcy
- 12019227
- Reverse Split Ratio
- 1:10 (effective Sept 2025)
- Proposed Reverse Split Range
- 1:3 to 1:30
Price after filing
Close on the filing date to close N calendar days later (from $0.28). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.